Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)
Principal Investigator
Steven Lin, MD PhD
Status
Terminated
Date Opened To Accrual
January 04 2019
Date Closed to Accrual
December 12 2024
Date of Study Termination
September 04 2025
Disease Site
Lung [LU]
Non-small Cell Lung Cancer
Phase
I
Developmental Therapeutics
No
Primary Objective
To evaluate if the addition of MEDI4736 (durvalumab) to two schedules of radiation therapies (60 Gy in 30 fractions or 60 Gy in 15 fractions) is safe.
Patient Population
Unresectable or inoperable, non-metastatic stage II-III Non-Small Cell Lung Cancer patients who have PD-L1 high expressing tumors (>=50%) within 60 days prior to registration.
Target Accrual
24